Endotracheal epinephrine effect on COVID-19

Evaluation of endotracheal epinephrine effect on Increasing Oxygen Saturation level in COVID-19 patients with severe pulmonary involvement

Status

Recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT20210613051560N1

Enrollment

Registered

2021-12-20

Start date

2021-12-22

Completion date

Unknown

Last updated

2022-01-11

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

COVID-19. Pneumonia due to SARS-associated coronavirus

Interventions

Intervention 1: Intervention group: Patients with severe COVID-19 under mechanical ventilation who receive intratracheal epinephrine. At the beginning of enrollment of patients in this group, for eac

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Inclusion criteria

Inclusion criteria: PCR positive for COVID-19 Tachypnea, cough and fever at the time of admission Under aggressive mechanical ventilation Pulmonary involvement in lung imaging

Exclusion criteria

Exclusion criteria: History of cardiovascular diseases History of brain diseases History of pulmonary diseases Pregnancy

Design outcomes

Primary

Measure	Time frame
Oxygen saturation. Timepoint: Oxygen saturation is measured before intervention and 5, 10, 30 and 60 minutes after intervention. Method of measurement: Using pulse oximetry and ABG.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactTaraneh Naghibi

Zanjan University of Medical Sciences

tnaghibi@zums.ac.ir+98 24 3342 0651

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026